Single-Session Percutaneous Mechanical Thrombectomy Using the AspirexS Device Plus Stenting for Acute Iliofemoral Deep Vein Thrombosis: Safety, Efficacy, and Mid-Term Outcomes.
Fiche publication
Date publication
juillet 2020
Journal
Diagnostics (Basel, Switzerland)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LOFFROY Romaric
Tous les auteurs :
Loffroy R, Falvo N, Guillen K, Galland C, Baudot X, Demaistre E, Fréchier L, Ledan F, Midulla M, Chevallier O
Lien Pubmed
Résumé
To assess the safety, efficacy and mid-term outcomes of single-session percutaneous mechanical thrombectomy (PMT) for acute symptomatic iliofemoral deep vein thrombosis (DVT) using the AspirexS device. Retrospective review of 30 patients (women, 23; mean age, 45.5 ± 19.9 years; range, 17-76) who underwent PMT with the 10-French AspirexS device (Straub Medical AG, Wangs, Switzerland) for acute DVT between December 2015 and March 2019. Procedures were performed by popliteal ( = 22) or jugular ( = 7) approach, or both ( = 1). Mean time from diagnosis to PMT was 5.5 ± 4.6 days (range, 2-11). Successful thrombus removal and venous patency restoration were achieved in all patients (100%). Fluid removal was 307.8 ± 66.1 mL (range, 190-410). Additional venous stenting rate was 100%. Mean procedural time was 107.3 ± 33.9 min (range, 70-180). No major complication occurred. The patient's postprocedural course was uneventful in all cases, with hospital discharge within 2 days in 83.3%. Early in-stent rethrombosis occurred within 1 week in 3 patients, successfully managed by endovascular approach. Secondary stent patency rate was 86.7% at a mean follow-up of 22.3 ± 14.2 months (range, 6-48), as assessed by Duplex ultrasound. Single-session of PMT using the AspirexS device is a safe and effective therapeutic option in patients presenting with acute symptomatic iliofemoral DVT.
Mots clés
acute iliofemoral thrombosis, deep vein thrombosis, endovascular treatment, percutaneous mechanical thrombectomy, thrombolysis
Référence
Diagnostics (Basel). 2020 Jul 30;10(8):